Literature DB >> 6329116

Pharmacological studies on the mode of action of flavoxate.

P Cazzulani, R Panzarasa, C Luca, D Oliva, G Graziani.   

Abstract

Previous studies on the mode of action of flavoxate have shown that the drug exerts a selective and direct muscle relaxant activity. In order to study the mode of action of flavoxate, the following activities were investigated: calcium blocking, inhibition of cyclic AMP phosphodiesterase (PDE), local anaesthetic activity, the effects on the synthesis and release of prostaglandins. In the K+-depolarized guinea-pig taenia coli, contracted by CaCl2, flavoxate and papaverine showed a moderate calcium antagonistic activity. Anticholinergic drugs, such as atropine and emepronium, did not exert a similar action. The antispasmodic activity of a drug can be correlated with inhibition of cyclic AMP phosphodiesterase, and since papaverine is a potent PDE inhibitor, we tested flavoxate for this activity. Flavoxate exerted a PDE inhibitory activity about three and five times greater than that of aminophylline in tissues homogenates of guinea-pig ureter and urinary bladder, respectively. It also showed the same local anaesthetic activity of lidocaine. Finally, the synthesis and release of prostaglandins by urinary bladder muscle in vitro have been investigated before and after treatment with flavoxate. Myolytic activity of papaverine and flavoxate do not involve inhibition of prostaglandins synthesis in rat urinary bladder in vitro. Therefore, the mode of action of flavoxate can be related to a superimposition of myotropic, calcium antagonistic and local anaesthetic activity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6329116

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  4 in total

Review 1.  Flavoxate in urogynecology: an old drug revisited.

Authors:  Murat Zor; Emin Aydur; Roger Roman Dmochowski
Journal:  Int Urogynecol J       Date:  2014-12-06       Impact factor: 2.894

Review 2.  Flavone acetic acid (LM 975, NSC 347512). A novel antitumor agent.

Authors:  P J O'Dwyer; D Shoemaker; D S Zaharko; C Grieshaber; J Plowman; T Corbett; F Valeriote; S A King; J Cradock; D F Hoth
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 3.  Current concepts in the treatment of disorders of micturition.

Authors:  K E Andersson
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

4.  Effects of flavoxate hydrochloride on voltage-dependent Ba2+ currents in human detrusor myocytes at different experimental temperatures.

Authors:  Toshihisa Tomoda; Hai-Lei Zhu; Kazuomi Iwasa; Manami Aishima; Atsushi Shibata; Narihito Seki; Seiji Naito; Noriyoshi Teramoto
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-10-02       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.